These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1839059)

  • 1. Parenteral peptide formulations: chemical and physical properties of native luteinizing hormone-releasing hormone (LHRH) and hydrophobic analogues in aqueous solution.
    Powell MF; Sanders LM; Rogerson A; Si V
    Pharm Res; 1991 Oct; 8(10):1258-63. PubMed ID: 1839059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of luteinizing hormone releasing hormone: effects of pH, temperature, pig skin, and enzyme inhibitors.
    Bi M; Singh J
    Pharm Dev Technol; 2000; 5(3):417-22. PubMed ID: 10934742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degradation kinetics of gonadorelin in aqueous solution.
    Hoitink MA; Beijnen JH; Bult A; van der Houwen OA; Nijholt J; Underberg WJ
    J Pharm Sci; 1996 Oct; 85(10):1053-9. PubMed ID: 8897270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution.
    Powell MF; Foster LC; Becker AR; Lee W
    Pharm Res; 1988 Aug; 5(8):528-32. PubMed ID: 3244663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-performance liquid chromatographic (HPLC) and HPLC-mass spectrometric (MS) analysis of the degradation of the luteinizing hormone-releasing hormone (LH-RH) antagonist RS-26306 in aqueous solution.
    Strickley RG; Brandl M; Chan KW; Straub K; Gu L
    Pharm Res; 1990 May; 7(5):530-6. PubMed ID: 2195493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of N-methyl substitution of the peptide bonds in luteinizing hormone-releasing hormone agonists.
    Haviv F; Fitzpatrick TD; Swenson RE; Nichols CJ; Mort NA; Bush EN; Diaz G; Bammert G; Nguyen A; Rhutasel NS
    J Med Chem; 1993 Feb; 36(3):363-9. PubMed ID: 8381183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.
    Chu NI; Chan RL; Hama KM; Chaplin MD
    Drug Metab Dispos; 1985; 13(5):560-5. PubMed ID: 2865103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoelectric focusing and capillary zone electrophoretic studies using luteinizing hormone releasing hormone and its analog.
    Heit MC; McFarland A; Bock R; Riviere JE
    J Pharm Sci; 1994 May; 83(5):654-6. PubMed ID: 8071815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced stability of codeine sulfate: effect of pH, buffer, and temperature on the degradation of codeine in aqueous solution.
    Powell MF
    J Pharm Sci; 1986 Sep; 75(9):901-3. PubMed ID: 3783462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis.
    Raiman J; Koljonen M; Huikko K; Kostiainen R; Hirvonen J
    Eur J Pharm Sci; 2004 Feb; 21(2-3):371-7. PubMed ID: 14757511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide liquid crystals: inverse correlation of kinetic-formation and thermodynamic stability in aqueous solution.
    Powell MF; Fleitman J; Sanders LM; Si VC
    Pharm Res; 1994 Sep; 11(9):1352-4. PubMed ID: 7816768
    [No Abstract]   [Full Text] [Related]  

  • 12. Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical/tubular niosomes.
    Arunothayanun P; Turton JA; Uchegbu IF; Florence AT
    J Pharm Sci; 1999 Jan; 88(1):34-8. PubMed ID: 9874699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of the potential utility of LHRH agonists and antagonists for fertility control.
    Vickery BH
    J Steroid Biochem; 1985 Nov; 23(5B):779-91. PubMed ID: 3001420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of gonadorelin and triptorelin in aqueous solution.
    Helm VJ; Müller BW
    Pharm Res; 1990 Dec; 7(12):1253-6. PubMed ID: 2151342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist.
    Chan RL; Chaplin MD
    Biochem Biophys Res Commun; 1985 Mar; 127(2):673-9. PubMed ID: 3156598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro drug release behavior of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method.
    Niwa T; Takeuchi H; Hino T; Kunou N; Kawashima Y
    J Pharm Sci; 1994 May; 83(5):727-32. PubMed ID: 8071830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer.
    Sanders LM; Kell BA; McRae GI; Whitehead GW
    J Pharm Sci; 1986 Apr; 75(4):356-60. PubMed ID: 2941563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunoassay of nafarelin ([ 6-(3-(2-naphthyl)-D-alanine)]-luteinizing hormone-releasing hormone) in plasma or serum.
    Nerenberg C; Foreman J; Chu N; Chaplin MD; Kushinsky S
    Anal Biochem; 1984 Aug; 141(1):10-6. PubMed ID: 6238549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation kinetics of metronidazole in solution.
    Wang DP; Yeh MK
    J Pharm Sci; 1993 Jan; 82(1):95-8. PubMed ID: 8429500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term stability of aqueous solutions of luteinizing hormone-releasing hormone assessed by an in vitro bioassay and liquid chromatography.
    Shi YF; Sherins RJ; Brightwell D; Gallelli JF; Chatterji DC
    J Pharm Sci; 1984 Jun; 73(6):819-21. PubMed ID: 6376770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.